Repligen ( (RGEN) ) has shared an announcement.
On November 6, 2026, Repligen issued $1.0 billion of 0.25% convertible senior notes due 2031 through previously announced exchange and subscription transactions. About $541.4 million of the new notes replaced $456.8 million of 1.00% notes due 2028, while $458.6 million was issued for cash.
The exchanged 2028 notes were canceled, leaving about $143.2 million outstanding on unchanged terms. The privately placed, unregistered securities were sold under Securities Act exemptions to institutional accredited investors and qualified institutional buyers, resulting in a lower-coupon, longer-dated debt structure and additional cash financing.
The most recent analyst rating on (RGEN) stock is a Buy
with a $207.00 price target.
To see the full list of analyst forecasts on Repligen stock,
see the RGEN Stock Forecast page.
Spark’s Take on RGEN Stock
According to Spark, TipRanks’ AI Analyst, RGEN is a Neutral.
The score is driven primarily by solid financial footing (strong cash generation and a healthy balance sheet) and supportive technical momentum, reinforced by an upbeat earnings call with raised 2026 guidance and a strong 2027 growth framework. These positives are tempered by weak valuation signals tied to current GAAP losses (negative P/E) and some near-term operational headwinds highlighted on the call (filtration softness and delayed equipment revenue conversion).
To see Spark’s full report on RGEN stock,
click here.
More about Repligen
Average Trading Volume: 1,187,130
Technical Sentiment Signal: Buy
Current Market Cap: $11.39B
See more data about RGEN stock on TipRanks’ Stock Analysis page.
Trending Articles:
This article was AI-generated from the company’s official filing, with automated quality checks and editorial spot-checks.


